[go: up one dir, main page]

MX9800719A - Proteinas de transporte y sus usos. - Google Patents

Proteinas de transporte y sus usos.

Info

Publication number
MX9800719A
MX9800719A MX9800719A MX9800719A MX9800719A MX 9800719 A MX9800719 A MX 9800719A MX 9800719 A MX9800719 A MX 9800719A MX 9800719 A MX9800719 A MX 9800719A MX 9800719 A MX9800719 A MX 9800719A
Authority
MX
Mexico
Prior art keywords
transport proteins
proteins
cells
methods
transport
Prior art date
Application number
MX9800719A
Other languages
English (en)
Inventor
Peter Francis Joseph O'hare
Gillian Daphne Elliott
Original Assignee
Marie Curie Cancer Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515568.5A external-priority patent/GB9515568D0/en
Priority claimed from GBGB9601570.6A external-priority patent/GB9601570D0/en
Application filed by Marie Curie Cancer Care filed Critical Marie Curie Cancer Care
Publication of MX9800719A publication Critical patent/MX9800719A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion se relaciona con proteínas de transporte, en particular VP22 y homologos de la misma, y con métodos para suministrar estas proteínas con cualquiera molécula asociada a una poblacion objetivo de células. Estas proteínas de transporte tienen aplicaciones en terapias de genes y métodos para dirigir agentes a células en las que se requiere objetivo de alta eficiencia.
MX9800719A 1995-07-28 1998-01-26 Proteinas de transporte y sus usos. MX9800719A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9515568.5A GB9515568D0 (en) 1995-07-28 1995-07-28 Transport proteins and their uses
GBGB9601570.6A GB9601570D0 (en) 1996-01-26 1996-01-26 Transport proteins and their uses

Publications (1)

Publication Number Publication Date
MX9800719A true MX9800719A (es) 1998-11-29

Family

ID=26307479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800719A MX9800719A (es) 1995-07-28 1998-01-26 Proteinas de transporte y sus usos.

Country Status (11)

Country Link
US (4) US6184038B1 (es)
EP (1) EP0845043B1 (es)
JP (1) JPH11510386A (es)
CN (1) CN1208438A (es)
AT (1) ATE365808T1 (es)
AU (1) AU705563B2 (es)
BR (1) BR9610058A (es)
CA (1) CA2227786A1 (es)
DE (1) DE69637147T2 (es)
MX (1) MX9800719A (es)
WO (1) WO1997005265A1 (es)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510386A (ja) * 1995-07-28 1999-09-14 マリー キュリー キャンサー ケア 輸送蛋白質およびそれらの使用
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
GB9705903D0 (en) * 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
AU7597998A (en) 1997-06-02 1998-12-21 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
DE69940805D1 (de) 1998-01-31 2009-06-10 Sinai School Medicine Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
GB9816761D0 (en) * 1998-07-31 1998-09-30 Phogen Limited Herpesvirus preparations and their uses
PL346213A1 (en) 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
DE19845420C2 (de) * 1998-10-02 2000-11-16 Deutsches Krebsforsch Interzelluläre Ausbreitung rekombinanter DNA
AU772847B2 (en) * 1998-11-12 2004-05-06 Invitrogen Corporation Transfection reagents
US6316252B1 (en) * 1998-12-17 2001-11-13 Wisconsin Alumni Research Foundation Biotherapeutic delivery system
WO2000053722A2 (en) * 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
JP2002539839A (ja) * 1999-03-31 2002-11-26 インヴィトロゲン・コーポレーション 転位ポリペプチドによる機能性タンパク質配列の送達
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6358739B1 (en) * 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
AU4342900A (en) * 1999-04-12 2000-11-14 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
US6451601B1 (en) 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
DE19933089A1 (de) * 1999-07-15 2001-01-18 Max Delbrueck Centrum Mittel zur Gewerbsregeneration
US20030219826A1 (en) * 1999-09-01 2003-11-27 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
EP1210362A2 (en) 1999-09-01 2002-06-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
KR20020048944A (ko) 1999-09-30 2002-06-24 프레드 헛친슨 켄서 리서치 센터 면역학적으로 중요한 ｈｓｖ 항원, 그의 확인방법 및 용도
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DE19955576B4 (de) * 1999-11-18 2008-02-28 Faustus Forschungs Cie. Translational Cancer Research Gmbh Transferverbindungen, ihre Herstellung und ihre Verwendung
GB9930519D0 (en) * 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
DE10001230A1 (de) * 2000-01-13 2001-08-02 Deutsches Krebsforsch Immunisierungsmittel
US6688084B2 (en) * 2000-03-24 2004-02-10 International Paper Company Automated bulk box strapper
AU2001290520A1 (en) * 2000-08-01 2002-02-13 The Johns Hokpins University Intercellular transport protein linked to an antigen as a molecular vaccine
GB0022101D0 (en) * 2000-09-08 2000-10-25 Phogen Ltd Delivery of substances to cells
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1420821B8 (en) 2001-07-31 2011-02-02 University of Washington Immunologically significant herpes simplex virus antigens and methods for using same
WO2003042239A1 (en) * 2001-11-12 2003-05-22 Stichting Sanquin Bloedvoorziening Peptides inhibiting signaling by ras-like gtpases
CA2486449A1 (en) * 2002-05-17 2004-02-19 Automated Cell, Inc. Determination of protein function
AU2003254089A1 (en) * 2002-07-19 2004-02-09 Myriad Genetics, Inc Method and composition for treating and preventing herpesvirus infection
EP1590363A4 (en) 2002-09-09 2006-11-02 Dana Farber Cancer Inst Inc BH3-PEPTIDES AND METHOD FOR THEIR USE
JP2006517790A (ja) * 2003-01-09 2006-08-03 インヴィトロジェン コーポレーション ポリペプチド−核酸複合体の細胞の送達および活性化
IL157787A (en) * 2003-09-07 2010-12-30 Mosaid Technologies Inc Modular outlet for data communications network
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
GB0321311D0 (en) * 2003-09-12 2003-10-15 Phogen Ltd Delivery of substances to cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
WO2008036060A2 (en) 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
EP1970446B1 (en) 2005-12-13 2011-08-03 Kyoto University Nuclear reprogramming factor
CA2634824A1 (en) 2005-12-23 2007-06-28 Nicolas Fasel Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
WO2008021484A2 (en) 2006-08-16 2008-02-21 Eutropics Pharmaceuticals Assay system to identify therapeutic agents
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
GB0724253D0 (en) * 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
ES2722198T3 (es) 2008-05-02 2019-08-08 Univ Kyoto Método de reprogramación nuclear
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (en) 2009-04-03 2013-05-01 Univ Washington ANTIGENIC HSV-2 PEPTIDE AND METHOD OF USE THEREOF
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
GB0917792D0 (en) * 2009-10-12 2009-11-25 Fermentas Uab Delivery agent
JP5726282B2 (ja) * 2010-03-18 2015-05-27 スパイバー テクノロジーズ アーベーＳｐｉｂｅｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ａｂ タンパク質及びポリペプチドの産生
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US8785192B2 (en) 2010-07-07 2014-07-22 Cellular Dynamics International, Inc. Endothelial cell production by programming
DK2902035T3 (en) 2010-10-14 2018-09-24 Xigen Inflammation Ltd METHODS FOR TREATING MUSCLE DYROPHY
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
EP2643459B1 (en) 2010-11-24 2017-09-27 Takara Bio USA, Inc. Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same
EP2673358B1 (en) 2011-02-08 2019-01-09 FUJIFILM Cellular Dynamics, Inc. Hematopoietic precursor cell production by programming
BR112014013041A2 (pt) 2011-11-30 2019-09-24 Xigen Inflammation Ltd uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
JP6433896B2 (ja) 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸
US10393733B2 (en) 2012-09-19 2019-08-27 Dana-Farber Cancer Institute, Inc. Dynamic BH3 profiling
WO2015197098A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP3013353B1 (en) 2013-06-26 2021-04-21 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206426A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2016055160A2 (en) 2014-10-08 2016-04-14 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015042249A1 (en) 2013-09-19 2015-03-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
HK1251655A1 (zh) 2015-04-20 2019-02-01 Tolero Pharmaceuticals, Inc. 通过线粒体分析预测对阿伏西地的应答
CA2983022C (en) 2015-04-27 2023-03-07 Dana-Farber Cancer Institute, Inc. High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
EP4086264B1 (en) 2015-05-18 2023-10-25 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
US10568887B2 (en) 2015-08-03 2020-02-25 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
MX2019007332A (es) 2016-12-19 2019-11-18 Tolero Pharmaceuticals Inc Péptidos indicadores y métodos para caracterizar sensibilidad.
EP3612191A4 (en) 2017-04-19 2020-12-30 Cedars-Sinai Medical Center METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCLE DYSTROPHY
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
AU2019391097B2 (en) 2018-12-04 2025-07-03 Sumitomo Pharma America, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP7589159B2 (ja) 2019-02-26 2024-11-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
JP2025505052A (ja) 2021-01-24 2025-02-20 デイヴィッド フォレスト マイケル Ａｔｐ合成酵素の阻害剤－美容および治療への使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312681B1 (no) 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US6251395B1 (en) * 1993-12-23 2001-06-26 W. Michael Gallatin Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies
FR2736915B1 (fr) 1995-07-19 1997-08-22 Rhone Poulenc Rorer Sa Variants de la proteine p53 et utilisations therapeutiques
JPH11510386A (ja) * 1995-07-28 1999-09-14 マリー キュリー キャンサー ケア 輸送蛋白質およびそれらの使用
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses

Also Published As

Publication number Publication date
JPH11510386A (ja) 1999-09-14
WO1997005265A1 (en) 1997-02-13
EP0845043B1 (en) 2007-06-27
CA2227786A1 (en) 1997-02-13
US20020039765A1 (en) 2002-04-04
US6184038B1 (en) 2001-02-06
DE69637147T2 (de) 2008-03-06
BR9610058A (pt) 1999-07-27
ATE365808T1 (de) 2007-07-15
EP0845043A1 (en) 1998-06-03
AU6623996A (en) 1997-02-26
DE69637147D1 (de) 2007-08-09
US20060051869A1 (en) 2006-03-09
US6521455B2 (en) 2003-02-18
US20030219859A1 (en) 2003-11-27
AU705563B2 (en) 1999-05-27
CN1208438A (zh) 1999-02-17

Similar Documents

Publication Publication Date Title
MX9800719A (es) Proteinas de transporte y sus usos.
IL123641A0 (en) Circular dna molecule with conditional origin of replication method for preparing the same and use thereof in gene therapy
BG102554A (en) Vectors and methods for gene transfer into cells
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
GB2338237A (en) In vitro peptide or protein expression library
EE9800185A (et) Komplementaarsed adenoviirusvektorsüsteemid ja rakuliinid
BRPI9811940A (pt) vetor de expressão para um polipeptídeo de ligação da interleucina-18 (il-18-bp), célula hospedeira procariótica transformada com o referido vetor, processo para produção de il-18-bp, proteína de fusão compreendendo o referido polipeptídeo, bem como il-18bp modificada.
TR199501134A2 (tr) Memeli ve viral proteinleri asiri ifade edilmesi.
DK0941318T3 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
MX9603532A (es) Sistema de suministro de acido nucleico, metodo de sintesis y sus usos.
HU9502920D0 (en) New bacillus thuringiensis strains and their insecticidal proteins
WO1995013095A3 (en) Therapy
AU3477295A (en) Modified proteins
NZ304570A (en) Neurone-restrictive silencer factor proteins, nucleic acids and antibodies thereto
AU3677095A (en) Radioactive phosphorous labeling of proteins for targeted radiotherapy
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
AU6028898A (en) Methods for cultivating cells and propagating viruses
EP0754757A3 (en) A plant promoter and an application thereof
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
AU8991098A (en) Regulation of protein secretion
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
GB9723825D0 (en) Nuclear targeting by means of bacterial proteins
CA2475337A1 (en) Methods for cultivating cells and propagating viruses
ATE266418T1 (de) Malignitätsunterdrückung durch verwendung von ribonucleotid reductase r1
IT1262997B (it) Composto proteico e sequenze nucleotidiche codificanti per esso.